Sign up Australia
Proactive Investors - Run By Investors For Investors

Regeneus welcomes positive step forward for Progenza’s US patent

Progenza is the company’s lead cell therapy technology platform.
filing cabinet with file marked 'patents'
Progenza is being developed to treat osteoarthritis and other musculoskeletal diseases

Regeneus Ltd (ASX:RGS) welcomes the United States Patent Office’s notice of allowance for issuance of a patent covering the composition and use of Progenza.

Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of knee osteoarthritis and other inflammatory conditions.

READ: Regeneus director supports stem cell technology through on-market purchase

Issuance of the patent for United States Patent Application No. 14/342479 entitled ‘Therapeutics using adipose cells and cell secretions’ will provide commercial rights in the United States through to 2032.

Corresponding patents have been granted in Australia and Japan and are being pursued for grant in other key territories including Europe.

View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use